Amicus Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
05. Januar 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference, being held...
European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease
03. Dezember 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA)...
Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference
24. November 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th...
Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism
22. November 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of...
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
18. November 2021 07:00 ET
|
Amicus Therapeutics, Inc.
Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced Patients with High Unmet Need AT-GAA Deemed...
Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
11. November 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Stifel...
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates
09. November 2021 07:00 ET
|
Amicus Therapeutics, Inc.
3Q21 Total Galafold® Revenue of $79.5M – an 18% increase over 3Q20 Reiterating 2021 Revenue Guidance of $300M-$315M AT-GAA BLA and NDA for Pompe Disease Accepted for Review by the...
Amicus Therapeutics to Announce Third Quarter 2021 Financial Results on November 9, 2021
03. November 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 9, 2021 at...
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
29. September 2021 06:30 ET
|
Amicus Therapeutics, Inc.
Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding ...
U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease
29. September 2021 06:30 ET
|
Amicus Therapeutics, Inc.
FDA Sets PDUFA Target Action Date of May 29, 2022 for the New Drug Application and July 29, 2022 for the Biologics License Application On Track for MAA Submission in the Fourth Quarter of this Year ...